Invest now
Zydus Lifesciences share price
Balanced risk
- ₹1,155.90(0.13%)July 16, 2026 15:29:39 PM IST
- NSE
- BSE
- Vol : 1.01 M (NSE + BSE)Last 20 day avg : 1.65 M
Zydus Lifesciences is trading 0.13% upper at Rs 1,155.90 as compared to its last closing price. Zydus Lifesciences has been trading in the price range of 1,165.10 & 1,147.70. Zydus Lifesciences has given 26.53% in this year & 0.78% in the last 5 days. Zydus Lifesciences has TTM P/E ratio 17.39 as compared to the sector P/E of 25.82.There are 30 analysts who have initiated coverage on Zydus Lifesciences. There are 6 analysts who have given it a strong buy rating & 9 analysts have given it a buy rating. 3 analysts have given the stock a sell rating.The company posted a net profit of 1,272.50 Crores in its last quarter.Listed peers of Zydus Lifesciences include Cipla (-0.69%), Torrent Pharmaceuticals (-0.30%), Divi's Laboratories (0.48%).The Mutual Fund holding in Zydus Lifesciences was at 5.12% in 30 Jun 2026. The MF holding has increased from the last quarter. The FII holding in Zydus Lifesciences was at 6.89% in 30 Jun 2026. The FII holding has decreased from the last quarter.
- Overview
- Financials
- Forecast
- Technical Analysis
- Peers
- Shareholding
- About the company
- FAQ
Overview
- 1 D
- 5 D
- 1 M
- 3 M
- 6 M
- 1 Y
- 5 Y
- MAX
Loading...
Key Metrics
Updated on 16 Jul 2026, 05:11 PM IST
- BetaLow volatility0.52Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
- Debt To EquityHigher than industry0.46The debt-to-equity ratio, indicating a company's financial leverage.
- Dividend YieldLower than industry0.09Annual dividends as a percentage of the stock price.
- PEG RatioIndicates undervaluation0.61The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
- P/E-Price-to-earnings ratio based on trailing 12-month earnings
- P/B-The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
Price range
Day Range
|
| ||||
52 week range
|
| ||||
Zydus Lifesciences News
Zydus Lifesciences Peers
Return Comparison
Peers Comparison
Names | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Cipla | 1,428.00 | -0.69 | 1,15,360.31 | 22.95 | 3.87 | 0.87 | 0.81 |
| Torrent Pharmaceuticals | 5,002.75 | -0.30 | 1,69,368.61 | 67.32 | 17.1 | 0.83 | 17.62 |
| Divi's Laboratories | 7,319.75 | 0.48 | 1,94,316.36 | 78.61 | 11.52 | 0.46 | 0.01 |
| Dr Reddy's Laboratories | 1,223.90 | -0.48 | 1,02,151.19 | 18.63 | 3.14 | 0.63 | 2.34 |
| Sun Pharmaceutical Industries | 1,951.30 | -0.06 | 4,68,171.21 | 36.24 | 5.77 | 0.92 | 0.50 |
Mutual Fund Ownership
View allZydus Lifesciences Corporate Actions
View all- Board Meetings
- AGM
- Dividends
- Bonus
- Split
- Rights
| Meeting Date | Purpose |
|---|---|
| 2026-05-19 | Audited Results, Dividend & Buy Back |
| 2026-02-09 | Quarterly Results |
| 2025-11-06 | Quarterly Results & Fund raising |
| 2025-08-12 | Quarterly Results |
| 2025-05-20 | Audited Results & Final Dividend |
About the company Zydus Lifesciences
- IndustryBiotechnology & Drugs
- ISININE010B01027
- BSE Code532321
- NSE CodeZYDUSLIFE
Zydus Lifesciences Limited is an India-based global life sciences company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The Company is engaged in the business of integrated pharmaceutical operations. Its product portfolio includes active pharmaceutical ingredients (API), human formulations, animal health and veterinary, health, and wellness products. Its products include India formulations, Generics and Zydus biologics. The Company's products include Lipaglyn and Bilypsa (Saroglitazar), Ujvira (Trastuzumab emtansine biosimilar), Exemptia (Adalimumab biosimilar), Vivitra (Trastuzumab biosimilar) and Bryxta (Bevacizumab biosimilar). Its Zydus biologics covers various therapeutic areas, such as oncology, autoimmune disease, nephrology, inflammation, rheumatology, hepatology and infectious illnesses, among others. The Company has a global presence and markets its products in the United States, India, Europe and emerging markets.
Zydus Lifesciences Share Price FAQs
Zydus Lifesciences is trading at 1155.90 as on Thu Jul 16 2026 09:59:39. This is 0.13% upper as compared to its previous closing price of 1154.40.
The market capitalization of Zydus Lifesciences is 115204.94 Cr as on Thu Jul 16 2026 09:59:39.
The average broker rating on Zydus Lifesciences is Buy. The breakup of analyst rating is given below -
- 6 analysts have given a strong buy rating
- 9 analysts have given a buy rating
- 10 analysts have given a hold rating
- 3 analysts have given a sell rating
- 2 analysts have given a strong sell rating
The 52 wk high for Zydus Lifesciences is 1181.00 whereas the 52 wk low is 835.85
Zydus Lifesciences can be analyzed on the following key metrics -
- TTM P/E: 17.39
- Sector P/E: 25.82
- Dividend Yield: 0.09%
- D/E ratio: 0.46
Zydus Lifesciences reported a net profit of 5040.00 Cr in 2026.
The Mutual Fund Shareholding was 5.12% at the end of 30 Jun 2026.
Quick Links
EQUITY QUICK LINKS
Zydus Lifesciences QUICK LINKS
FROM MARKETS
RELATED LINKS
✕
Wait for it…
Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.